4.2 Article

Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study

Journal

MODERN RHEUMATOLOGY
Volume 20, Issue 1, Pages 46-53

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1007/s10165-009-0236-3

Keywords

Rheumatoid arthritis; Medical costs; Disease Activity Score; Observational cohort study; Health Assessment Questionnaire

Categories

Funding

  1. Asahikasei Kuraray Medical Co., Ltd.
  2. Asahikasei Pharma Corporation
  3. Astellas Pharma Inc.
  4. AstraZeneca K. K.
  5. Sanofi-Aventis
  6. Abbott Japan Co. Ltd.
  7. Eisai Co., Ltd.
  8. Kaken Pharmaceutical Co., Ltd.
  9. Kissei Pharmaceutical Co., Ltd.
  10. GlaxoSmithKline K. K.
  11. Kowa Pharmaceutical Co. Ltd.
  12. Sekisui Medical Co., Ltd
  13. ZERIA Pharmaceutical Co., Ltd.
  14. Daiichi Fine Chemical Co., Ltd.
  15. Daiichi Sankyo Co., Ltd.,
  16. Taishotoyama Pharmaceutical Co., Ltd.
  17. Dainippon Sumitomo Pharma Co., Ltd.
  18. Nippon Chemiphar Co., Ltd.
  19. Novartis Pharma K. K
  20. Phizer Japan Inc.
  21. Bristol-Myers K. K
  22. Mitsubishi Chemical Medience Corporation
  23. Janssen Pharmaceutical K. K.
  24. UBC Japan Co., Ltd
  25. Wyeth K. K
  26. Sanwa Kagaku Kenkyusho Co., Ltd.
  27. Santen Pharmaceutical Co., Ltd.
  28. Otsuka Pharmaceutical Co., Ltd.
  29. Chugai Pharmaceutical Co.
  30. Torii Pharmaceutical Co., Ltd
  31. Mitsubishi Tanabe Pharma Corporation, Japan Tobacco Inc.
  32. Nippon Shinyaku Co., Ltd.
  33. Banyu Pharmaceutical Co., Ltd.
  34. Centocor Inc

Ask authors/readers for more resources

Our objective was to describe outpatient medical care costs of patients with rheumatoid arthritis (RA) in the prebiologics period in Japan. The outpatient costs of 6,771 RA patients (17,666 patient years) who were enrolled in an observational cohort study at the Institute of Rheumatology, Rheumatoid Arthritis (IORRA), in Tokyo, Japan, were calculated from the billing records dated from 2000 to 2004. Associations between outpatient costs and variables such as age, RA duration, RA disease activities, and disability levels were assessed. The average outpatient cost gradually increased (+7.7% in 4 years) from 271,498 JPY per year in 2000 to 292,417 JPY per year in 2004. Medications accounted for approximately 50% of total outpatient costs, which increased 29.6% during the 4 years. The outpatient costs increased in association with aging, longer RA duration, higher Disease Activity Score of 28 Joints (DAS28), and higher Japanese version of Health Assessment Questionnaire (J-HAQ) score. Generalized linear regression analysis revealed that both DAS28 and J-HAQ scores were the most significant factors associated with outpatient costs (p < 0.001). Outpatient costs for patients with RA increased year after year over the 4-year period under observation in Japan. Medical costs were higher with increasing RA disease activity and disability levels.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available